US Pharma MarketingBioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal
BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
BioMarin’s $270 million bet on Inozyme’s enzyme replacement therapy looks in trouble after the candidate only managed to hit one of the dual primary endpoints of a phase 3 study in children with a rare genetic disorder.
Source: FierceBiotech